BioSpace News Archive

Eli Lilly and Company (NYSE: LLY) plans to expand its manufacturing footprint in Indiana by investing $2.1 billion in two new manufacturing sites at Indiana’s LEAP Lebanon Innovation and Research District in Boone County.

Phenomix Sciences, a precision obesity biotechnology company, announces the launch of its biobanking registry and outcomes study.

A recently published peer-reviewed study comparing acute changes in the upper body with pulsed direct current and high load exercises found that short-term training with the Neubie® neuromuscular electrical stimulation (NMES) device results in similar responses as traditional high load training in areas of increased muscle thickness.

Galapagos NV (Euronext & Nasdaq: GLPG) will present 11 abstracts at the European League Against Rheumatism (EULAR) congress 2022, 01-04 June, taking place in Copenhagen, Denmark.

Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced that management will participate in three upcoming investor conferences.

Leidos (NYSE: LDOS), a FORTUNE 500® science and technology leader, will participate in the Jefferies Virtual IT Services Summit.

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Ryan Spencer, Chief Executive Officer and Kelly MacDonald, Chief Financial Officer, will participate in a fireside chat during the William Blair 42nd Annual Growth Stock Conference.

Hanger, Inc. (NYSE: HNGR), a leading provider of orthotic and prosthetic (O&P) patient care services and solutions, announced today that members of its management team will participate in presentations and meetings at the Jefferies Healthcare Conference taking place June 8-10, 2022.

Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, provided an update on the clinical development plan of its lead candidate, OVX836.

Bavarian Nordic A/S announced the signing of a supply contract with an undisclosed country for the Company’s smallpox vaccine with the aim to ensure sufficient supply to meet the country’s requirements for vaccinating individuals at risk for monkeypox in the short to medium term.